The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
DeNavas-WaltCProctorBDSmithJC. Income, poverty, and health insurance coverage in the United States: 2012. Current population reports. Available at: https://www.census.gov/prod/2013pubs/p60-245.pdf. Accessed October 12 2015.
WalkerGVGrantSRGuadagnoloBA. Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol2014;32:3118–3125.
WardEMFedewaSACokkinidesVVirgoK. The association of insurance and stage at diagnosis among patients aged 55 to 74 years in the national cancer database. Cancer J2010;16:614–621.
HalpernMTWardEMPavluckAL. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol2008;9:222–231.
FedewaSAEtzioniRFlandersWD. Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiol Biomarkers Prev2010;19:2437–2444.
MahalBAAizerAAZiehrDR. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis2014;17:273–279.
StephensonAJScardinoPTEasthamJA. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst2006;98:715–717.
CooperbergMRPastaDJElkinEP. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol2005;173:1938–1942.
KlotzLZhangLLamA. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol2009;28:126–131.
VickersABennetteCSteineckG. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol2012;62:204–209.
HeidenreichABastianPJBellmuntJ. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol2014;65:467–479.
CulpSHSchellhammerPFWilliamsMB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol2014;65:1058–1066.
FossatiNTrinhQDSammonJ. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol2015;67:3–6.
O'KellyFThomasAMurrayD. Can delayed time to referral to a tertiary level urologist with an abnormal PSA level affect subsequent Gleason grade in the opportunistically screened population?Prostate2013;73:1263–1269.
Dall'eraMAHosangNKonetyB. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol2009;181:1622–1627; discussion 1627.
SwanJBreenNCoatesRJ. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer2003;97:1528–1540.
MoyerVAU.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med2012;157:120–134.
CarlssonSVickersAJRoobolM. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol2012;30:2581–2584.
WolfAMWenderRCEtzioniRB. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin2010;60:70–98.
AizerAAWilhiteTJChenMH. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer2014;120:1532–1539.
EllimoottilCMillerDC. Anticipating the effect of the Patient Protection and Affordable Care Act for patients with urologic cancer. Urol Oncol2014;32:55–58.